Alzheimer’s
New study argues the importance of existing anti-inflammatory drugs in fighting dementia
May 3, 2018Research and Development Alzheimer's, dementia, pharma
Research into dementia has waned in recent times as researchers struggle to pin down concrete advancements, leading to the withdrawal …
Celgene bucks trend to strengthen neuroscience pipeline
March 21, 2018Research and Development, Sales and Marketing Alzheimer's, Celgene, Prothena, biotech, drugs, neuroscience, pharma, pharmaceutical
Celgene has gone against industry movement to back out of the neuroscience area by putting down a potential $2.2 billion …
Top Ten most popular articles on Pharmafile.com this week
March 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
EMA set to also revise guidelines of Alzheimer’s trials
February 28, 2018Medical Communications Alzheimer's, EMA, FDA, biotech, drugs, pharma, pharmaceutical
The EMA, following on from the FDA’s lead earlier this month, has announced that it will revise its guidelines on …
Top Ten most popular articles on Pharmafile.com this week
February 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease
It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …
AbbVie turns to tau for Alzheimer’s in $1.1bn deal
February 21, 2018Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical
Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …
FDA weighs up divisive change to Alzheimer’s drug assessment
February 16, 2018Medical Communications Alzheimer's, FDA, biotech, drugs, pharma, pharmaceutical
Alzheimer’s disease (AD) is an area badly in need of a treatment, the problem is that this prospect seems to …
Biogen shares hit by key Alzheimer’s drug concerns
February 15, 2018Research and Development Alzheimer's, Biogen, MSD, Merck, biotech, drugs, pharma, pharmaceutical
Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …
MSD shuts down Phase 3 trial in prodromal Alzheimer’s
February 14, 2018Research and Development Alzheimer's, MSD, pharma, verubecestat
Another blow has been dealt to the field of Alzheimer’s research as MSD announces yet another trial failure of a …
Boehringer terminates Alzheimer’s candidate after Phase 2 failure
February 12, 2018Research and Development, Sales and Marketing Alzheimer's, Boehringer Ingelheim, dementia, pharma
Boehringer Ingelheim has announced its intention to halt development of its candidate BI 409306 in the treatment of Alzheimer’s after …
Top Ten most popular articles on Pharmafile.com this week
February 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Alzheimer's, Apotex, AstraZeneca, Brexit Health Alliance, CDC, Duchenne Muscular Dystrophy, EMA, Italy, Sanofi, amazon, brexit, santhera, top ten
It’s the first Friday of February, and it’s time for another recap of the top ten articles most popular with …
New blood test for Alzheimer’s offers hope
February 1, 2018Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical
To say January was a bleak month for Alzheimer’s research would be something of an understatement: Pfizer ducked out of …
Top Ten most popular articles on Pharmafile.com this week
January 26, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abcam, Alzheimer's, Dr Reddy's, GSK, J&J, JJ, Reckitt Benckiser, Remicade, Sanofi, influenza, opioid crisis, opioids, top ten, valproate
As we come to the end of January, it’s Friday again – time for another rundown of the top ten …
Senescent cell findings provides Parkinson’s treatment clue
January 25, 2018Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical
Senescent cells are the dormant state that cells shift to in response to certain stressors, it is thought that they …
Amyloid pathway doubts after latest Alzheimer’s failure
January 25, 2018Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical
There has been another drug failure in a large Phase 3 that once again crushes a hope for a possible …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
